A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib In Combination With Physician's Choice Of Enzalutamide Or Abiraterone Acetate/Prednisone In Metastatic Castration-resistant Prostate Cancer With Dna Damage Repair Deficiencies
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Talazoparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TALAPRO-2
- Sponsors Pfizer
- 19 Mar 2018 Planned End Date changed from 22 Jul 2023 to 17 Mar 2024.
- 19 Mar 2018 Planned primary completion date changed from 29 Mar 2022 to 30 May 2022.
- 12 Jan 2018 New trial record